This Webinar covers the introduction of the CardioExcyte 96, a hybrid device for impedance- and MEA-type recordings from intact, beating networks of stem cell-derived cardiomyocytes.
"Human Cor.4U cardiomyocytes and the CardioExcyte 96: A perfect match to assess cardiotoxicity in vitro"
Dr. Ralf Kettenhofen, Axiogenesis, Cologne, Germany
"First experience with new CiPA projects on the CardioExcyte 96"
Dr. Liudmila Polounchuk, Hoffmann-La Roche, Basel, Switzerland
"New advances of the CardioExcyte 96: Pacing, Environmental Control & Cardiotoxicity Testing According to CiPA-Standards"
Dr. Sonja Stoelzle-Feix, Director Scientific Affairs, Nanion Technologies, Munich Germany
Nanion invites you to a webinar on the CardioExcyte 96 - a hybrid device for impedance- and MEA-type recordings from intact, beating networks of stem cell-derived cardiomyocytes.
Combining impedance- and MEA-recordings increases the significance of toxicity screens as both the contractility and the electrical excitability of the cellular network are taken into account.